Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates
dc.contributor.author | Karakus, Gozde Sir | |
dc.contributor.author | Tastan, Cihan | |
dc.contributor.author | Kancagi, Derya Dilek | |
dc.contributor.author | Yurtsever, Bulut | |
dc.contributor.author | Tumentemur, Gamze | |
dc.contributor.author | Demir, Sevda | |
dc.contributor.author | Turan, Raife Dilek | |
dc.contributor.author | Abanuz, Selen | |
dc.contributor.author | Cakirsoy, Didem | |
dc.contributor.author | Seyis, Utku | |
dc.contributor.author | Ozer, Samed | |
dc.contributor.author | Elibol, Omer | |
dc.contributor.author | Elek, Muhammer | |
dc.contributor.author | Ertop, Gurcan | |
dc.contributor.author | Arbale, Serap | |
dc.contributor.author | Elmas, Merve Acikel | |
dc.contributor.author | Hermsinlioglu, Canso | |
dc.contributor.author | Kocagoz, Ayse Sesin | |
dc.contributor.author | Ng, Ozden Hatirnaz | |
dc.contributor.author | Akyoney, Sezer | |
dc.contributor.author | Sahin, Ilayda | |
dc.contributor.author | Ozbek, Ugur | |
dc.contributor.author | Telci, Dilek | |
dc.contributor.author | Sahin, Fikrettin | |
dc.contributor.author | Yalcin, Koray | |
dc.contributor.author | Ratip, Siret | |
dc.contributor.author | Ovali, Ercument | |
dc.date.accessioned | 2023-02-21T12:38:00Z | |
dc.date.available | 2023-02-21T12:38:00Z | |
dc.date.issued | 2021-01-01 | |
dc.description.abstract | COVID-19 outbreak caused by SARS-CoV-2 created an unprecedented health crisis since there is no vaccine for this novel virus. Therefore, SARS-CoV-2 vaccines have become crucial for reducing morbidity and mortality. In this study, in vitro and in vivo safety and efficacy analyzes of lyophilized vaccine candidates inactivated by gamma-irradiation were performed. The candidate vaccines in this study were OZG-3861 version 1(V1), an inactivated SARS-CoV-2 virus vaccine, and SK-01 version 1 (V1), a GM-CSF adjuvant added vaccine. The candidate vaccines were applied intradermally to BALB/c mice to assess toxicity and immunogenicity. Preliminary results in vaccinated mice are reported in this study. Especially, the vaccine models containing GM-CSF caused significant antibody production with neutralization capacity in absence of the antibody-dependent enhancement feature, when considered in terms of T and B cell responses. Another important finding was that the presence of adjuvant was more important in T cell in comparison with B cell response. Vaccinated mice showed T cell response upon restimulation with whole inactivated SARS-CoV-2 or peptide pool. This study shows that the vaccines are effective and leads us to start the challenge test to investigate the gamma-irradiated inactivated vaccine candidates for infective SARS-CoV-2 virus in humanized ACE2+ mice. | |
dc.description.issue | 1 | |
dc.description.issue | MAR 11 | |
dc.description.volume | 11 | |
dc.identifier.doi | 10.1038/s41598-021-83930-6 | |
dc.identifier.uri | https://hdl.handle.net/11443/2325 | |
dc.identifier.uri | http://dx.doi.org/10.1038/s41598-021-83930-6 | |
dc.identifier.wos | WOS:000629623300078 | |
dc.publisher | NATURE RESEARCH | |
dc.relation.ispartof | SCIENTIFIC REPORTS | |
dc.title | Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1